Response to Immunotherapy in MMR-deficient Localized Colon Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

85 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-02-22

Study Completion Date

2024-06-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to evaluate the safety and efficacy of neoadjuvant treatment with pembrolizumab before colonic resection in patients with early-stage (I-III) deficient mismatch repair (dMMR) colon cancer (CC).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Electroporation and Immunotherapy in Metastatic Colorectal Cancer

NCT05609656

Metastatic Colorectal Cancer

TERMINATED PHASE2

Combining Intratumoral Flu Vaccine and Systemic Pembrolizumab in Patients With Early pMMR Colorectal Cancer

NCT05909423

Colorectal Cancer

NOT_YET_RECRUITING PHASE2

Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer

NCT07140679

Localized Colon Carcinoma Stage IIB Colon Cancer AJCC v8 Stage IIC Colon Cancer AJCC v8 +1 more

RECRUITING PHASE2

Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer

NCT06522919

Colorectal Cancer Metastatic Microsatellite Stable Colorectal Carcinoma Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer

RECRUITING PHASE2

Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)

NCT05518032

Metastatic Microsatellite Stable Colorectal Carcinoma Recurrent Colorectal Carcinoma Stage III Colorectal Cancer AJCC v8 +2 more

WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The trial is designed as an investigator-initiated, multicenter, prospective, single arm phase II study in patients with stage I-III dMMR CC scheduled for intended curative surgery to determine the efficacy of immunotherapy using pembrolizumab in the neoadjuvant setting. Patients will receive one dose of pembrolizumab (dosage of 4mg/kg, maximum of 400mg) following diagnosis. After 3 weeks a re-evaluation (to assess tumor response) will be performed, followed by standard surgery for resection of the tumor. Surgery will therefore be performed within 3 to 5 weeks after the dose of pembrolizumab treatment. Following the surgical resection the patients may receive post-operative chemotherapy in accordance with the clinical decision. The patients will be followed as per the standard Danish guidelines with CT scans at 1 and 3 years after surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colon Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Neoadjuvant pembrolizumab

Pembrolizumab

Group Type EXPERIMENTAL

Pembrolizumab

Intervention Type DRUG

One dosage of 4mg/kg (maximum of 400mg)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pembrolizumab

One dosage of 4mg/kg (maximum of 400mg)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Keytruda

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Histologically confirmed localized dMMR stage cT1N0M0 to cT4N2M0 (stage I to III) colon carcinoma.
2. Indication for elective curative intended surgery without neoadjuvant chemotherapy.
3. Age of ≥ 18 years.
4. Written informed consent.
5. Eastern Cooperative Oncology Group performance status of 0 or 1.
6. Adequate bone marrow function defined as:

* Hemoglobin ≥ 6.2 mmol/L or ≥ 10 g/dL.
* Absolute neutrophil count ≥ 1.5 × 109/L.
* Platelet count ≥ 100 × 109/L.
7. Adequate kidney function defined as:

o Estimated glomerular filtration rate ≥ 60 mL/min or creatinine ≤1.5 × upper limit of normal (ULN).
8. Adequate liver function defined as:

* Total bilirubin: ≤ 1.5 × ULN.
* Alanine aminotransferase: ≤ 2.5 × ULN.
* Alkaline phosphatase: ≤ 2.5 × ULN.
9. Follow the conditions regarding fertility, pregnancy, and lactation:

* Female and male participants of reproductive potential (PORP) must agree to avoid becoming pregnant or impregnating a partner, respectively, while receiving pembrolizumab and for 120 days after the dose.
* PORPs must use, or have their partner use, an acceptable method of contraception e.g. intrauterine device, contraceptive rod implanted into the skin, or hormonal contraceptive and male condom during heterosexual activity, while receiving pembrolizumab and for 120 days after the dose.
* Women of reproductive potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L HCG) within 72 hours prior to receiving pembrolizumab.
* Women must not be breastfeeding.

Exclusion Criteria

1. Any serious or uncontrolled medical disorder that, in the opinion of the investigator or treating physician, may increase the risk associated with study participation, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results.
2. Autoimmune disorders (except thyroiditis with replacement therapy and type I diabetes mellitus).
3. Prior treatment with ICIs or any other antibody/drug specifically targeting the T-cell co-stimulation or checkpoint pathways.
4. A known history of Human Immunodeficiency Virus, active chronic, or acute Hepatitis B or Hepatitis C.
5. A condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses \> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
6. Prior participation in another trial with an investigational medicinal product.
7. Received live vaccines within 30 days prior to pembrolizumab trial treatment. Seasonal influenza vaccines for injection are allowed.
8. A history of allergy to study drug components or a history of severe hypersensitivity reaction to any monoclonal antibody.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No